Wolverine Trading
PRTK

Wolverine Trading’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Wolverine Trading’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,044
Closed -$62K – 6773
2021
Q4 		$62K Buy
+14,044
New +$66.6K ﹤0.01% 5262
2021
Q3 		– Sell
-15,391
Closed -$84.8K – 7217
2021
Q2 		$105K Buy
15,391
+4,476
+41% +$36.2K ﹤0.01% 5390
2021
Q1 		$75K Sell
10,915
-7,625
-41% -$54.9K ﹤0.01% 5533
2020
Q4 		$115K Buy
+18,540
New +$109K ﹤0.01% 4430
2019
Q4 		– Sell
-13,407
Closed -$46.5K – 5384
2019
Q3 		$62K Buy
+13,407
New +$53.6K ﹤0.01% 4010
2018
Q4 		– Sell
-28,344
Closed -$215K – 5571
2018
Q3 		$275K Buy
28,344
+10,374
+58% +$105K ﹤0.01% 3847
2018
Q2 		$234K Hold
17,970
– – ﹤0.01% 4157
2018
Q1 		$234K Buy
+17,970
New +$268K ﹤0.01% 4157
2017
Q4 		– Sell
-16,385
Closed -$342K – 5668
2017
Q3 		$411K Buy
16,385
+7,613
+87% +$177K ﹤0.01% 2857
2017
Q2 		$223K Buy
+8,772
New +$194K ﹤0.01% 3462

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Wolverine Trading's PRTK Position: Q1 2022 in Review

Wolverine Trading sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 14,044 shares — an estimated $62K sold.

Wolverine Trading first reported a position in PRTK in Q2 2017 and held it in 10 quarters. The position peaked at $411K in Q3 2017. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

  • Wolverine Trading reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Wolverine Trading sold 14,044 Paratek Pharmaceuticals, Inc. shares in Q1 2022, an estimated $62K.
  • Wolverine Trading first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 10 quarters.
  • Wolverine Trading's Paratek Pharmaceuticals, Inc. position peaked at $411K in Q3 2017.
  • 100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Wolverine Trading's 13F filing for Q1 2022, filed 16 May 2022.